Mosanna Therapeutics announced today that it closed an $80 million Series A funding to support its sleep apnea therapy. The Redwood City, California-based company develops an easy-to-use nighttime nasal spray. It aims to treat obstructive sleep apnea by restoring the body’s natural airway control. The therapy could potentially end up offering an alternative to the […]
Funding Roundup
SpyGlass Pharma raises $75M for drug delivery platform
SpyGlass Pharma announced today that it closed a $75 million Series D financing round to support its drug delivery platform. Sands Capital led the financing round, with Gilde Healthcare also joining. Existing investors New Enterprise Associates (NEA), RA Capital, Vensana Capital, Samsara BioCapital and Vertex Ventures HC participated. The company said funds support its drug […]
Senseonics closes public offering, private placement with Abbott
Senseonics (NYSE:SENS) announced that it closed its previously announced public offering and private placement with Abbott. Last week, the long-term continuous glucose monitor maker said it commenced an underwritten public offering of common stock worth $50 million. At the same time, it entered into a securities purchase agreement with another CGM maker — Abbott. Under […]
Senseonics opens $50M public offering, $25M private placement with Abbott
Senseonics (NYSE:SENS) announced today that it commenced an underwritten public offering of common stock worth $50 million. The long-term implantable continuous glucose monitor (CGM) maker expects to grant underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of stock offered in the public offering. All shares to be […]
Biolinq closes $100M Series C funding round for biosensor platform
Biolinq said today it has closed a $100 million Series C funding round to advance its biosensor platform. “This financing will bolster Biolinq’s commercial readiness efforts while we pursue regulatory approval for the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device,” Biolinq CEO Rich Yang said in a […]
Vaxess raises $9M to support drug delivery patch, GLP-1 work
Shelf-stable vaccine patch maker Vaxess Technologies announced today that it received an additional $9 million in funding. Participants in the latest funding round for Woburn, Massachusetts-based Vaxess included RA Capital Management and Engine Ventures. The company plans to use the funds to continue to advance its work in GLP-1 therapeutics and to expand manufacturing capabilities. It […]
Modular Medical announces $12M private placement
Modular Medical (Nasdaq:MODD) announced today that it entered into definitive subscription agreements worth proceeds of approximately $12 million. The insulin patch pump maker company entered the agreements with institutional and accredited investors for a private placement. It consists of the sale of units comprised of two shares of common stock with one warrant to purchase […]
Insulet expands Omnipod 5 to more countries, prices $450M offering
Insulet (Nasdaq:PODD) announced today that it made its Omnipod 5 automated insulin delivery system available in several new geographies. The company made Omnipod 5 available in Australia and has planned launches for Belgium, Canada and Switzerland in the near term. This follows the launch of Omnipod 5 in five new European countries at the start […]
New funding supports Vitasense non-invasive glucose monitoring tech
Startup Vitasense today said it secured significant funding to advance its non-invasive wearable glucose monitoring technology. Junior high innovator Max Kopp from Germantown Academy in Pennsylvania leads the diabetes management startup. Crown Wealth, with strategic collaboration from KB Global Holding and other top universities, provided the undisclosed funding. The company said its funding marks a […]
RenovoRx prices $12.1M offering
RenovoRx (Nasdaq:RNXT) announced that it priced an underwritten public offering of common stock worth proceeds of $12.1 million. Mountain View, California-based RenovoRx priced more than 11.5 million shares of common stock at $1.05 per share. It expects the proceeds to total approximately $12.1 million before deducting underwriting discounts, commissions and offering expenses. The company plans […]
